The changing landscape of breast cancer clinical research: ESMO-Award lecture, ECCO-9 Hamburg, 18 September 1997PICCART, M. J.Annals of oncology. 1998, Vol 9, Num 2, pp 133-138, issn 0923-7534Article

Cancer du sein chez la femme jeune : faut-il intensifier les doses de la chimiothérapie ? = Breast cancer in the woman under 50: intensification of chimiotherapiePICCART, M. J.Pathologie et biologie. 1991, Vol 39, Num 9, pp 843-844, issn 0369-8114Article

Proposed treatment guidelines for HER2-positive metastatic breast cancer in EuropePICCART, M. J.Annals of oncology. 2001, Vol 12, pp 89-94, issn 0923-7534, SUP1Conference Paper

HER2 State-of-the-Art Conference, 21-23 November 1999, Montreux, SwitzerlandPICCART, M. J; PUNT, C. J. A.Annals of oncology. 2001, Vol 12, issn 0923-7534, 109 p., SUP1Conference Proceedings

La thérapie adjuvante systémique du cancer du sein : Mythes et controverses = Systemic adjuvant therapy for breast cancer : Facts and controverials issuesROY, J.-A; PICCART, M. J.Revue médicale de Bruxelles. 1996, Vol 17, Num 4, pp 267-270, issn 0035-3639Article

Stratégies thérapeutiques optimales dans le cancer épithélial de l'ovaire en 1997 = Optimal therapy for advanced epithelial ovarian cancer in 1997PICCART, M. J; NOGARET, J.-M.Revue médicale de Bruxelles. 1997, Vol 18, Num 4, pp 198-203, issn 0035-3639Conference Paper

Létrozole et cancer du sein hormonosensible de la femme ménopausée: actualités et perspectives = Letrozole and postmenopausal woman hormone-dependent breast cancer: state of the art and prospectsBERNARD-MANY, C; CARDOSO, F; PICCART, M. J et al.La Lettre du cancérologue (Boulogne). 2004, Vol 13, Num 1, pp 9-14, issn 1165-113X, 6 p.Article

Use and abuse of taxanes in the management of metastatic breast cancerBERNARD-MARTY, C; CARDOSO, F; PICCART, M. J et al.European journal of cancer (1990). 2003, Vol 39, Num 14, pp 1978-1989, issn 0959-8049, 12 p.Article

Current and future potential roles of the platinum drugs in the treatment of ovarian cancerPICCART, M. J; LAMB, H; VERMORKEN, J. B et al.Annals of oncology. 2001, Vol 12, Num 9, pp 1195-1203, issn 0923-7534Article

Progress in systemic therapy for breast cancer: an overview and perspectivesPICCART, M. J; CARDOSO, F.European journal of cancer. Supplement (1990). 2003, Vol 1, Num 2, pp 56-69, issn 1359-6349, 14 p.Article

HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients?PICCART, M. J; DI LEO, A; HAMILTON, A et al.European journal of cancer (1990). 2000, Vol 36, Num 14, pp 1755-1761, issn 0959-8049Article

Indications respectives de l'hormono-thérapie, de la chimiothérapie d'induction et de la chimiothérapie adjuvante dans le cancer du sein sans métastases à distance cliniquement décelables : Cancérologie : présent et futur du diagnostic et des thérapeutiques du cancer du sein = The place of hormonotherapy, preoperative chemo-therapy and adjuvant chemotherapy in early stage breast cancerROY, J. A; PICCART, M. J.Revue médicale de Bruxelles. 1995, Vol 16, Num 4, pp 242-244, issn 0035-3639Article

Anthracyclines active via the oral route : luxury or necessity?PICCART, M. J; DE VALERIOLA, D; TOMIAK, E et al.Annals of oncology. 1992, Vol 3, Num 3, pp 181-182, issn 0923-7534Article

Phase I and II clinical trials of trastuzumabBASELGA, J.Annals of oncology. 2001, Vol 12, pp 49-55, issn 0923-7534, SUP1Conference Paper

Targeting HER2 in other tumor typesSCHOLL, S; BEUZEBOC, P; POUILLART, P et al.Annals of oncology. 2001, Vol 12, pp 81-87, issn 0923-7534, SUP1Conference Paper

Evolution towards hormone independence of the MXT mouse mammarytumor is associated with a gradual change in its estrogen receptormolecular polymorphismPICCART, M. J; TRIVEDI, S; MAAROUFI, Y et al.Cancer biochemistry biophysics. 1998, Vol 16, Num 1-2, pp 169-182, issn 0305-7232Conference Paper

Docetaxel : an active new drug for treatment of advanced epithelial ovarian cancerPICCART, M. J; GORE, M; TEN BOKKEL HUININK, W et al.Journal of the National Cancer Institute. 1995, Vol 87, Num 9, pp 676-681, issn 0027-8874Article

Six-year results of a multimodality treatment strategy for locally advanced breast cancerPICCART, M. J; DE VALERIOLA, D; PARIDAENS, R et al.Cancer. 1988, Vol 62, Num 12, pp 2501-2506, issn 0008-543XArticle

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK Multicenter StudyTHERASSE, P; MAURIAC, L; WELNICKA-JASKIEWICZ, M et al.Journal of clinical oncology. 2003, Vol 21, Num 5, pp 843-850, issn 0732-183X, 8 p.Article

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sitesGANCBERG, D; DI LEO, A; CARDOSO, F et al.Annals of oncology. 2002, Vol 13, Num 7, pp 1036-1043, issn 0923-7534Article

HER2 status : A statistician's viewVALAGUSSA, P.Annals of oncology. 2001, Vol 12, pp 29-34, issn 0923-7534, SUP1Conference Paper

Mechanism of action of anti-HER2 monoclonal antibodiesBASELGA, J; ALBANELL, J.Annals of oncology. 2001, Vol 12, pp 35-41, issn 0923-7534, SUP1Conference Paper

The basic biology of HER2RUBIN, I; YARDEN, Y.Annals of oncology. 2001, Vol 12, pp 3-8, issn 0923-7534, SUP1Conference Paper

Tolerability in patients receiving trastuzumab with or without chemotherapyGIANNI, L.Annals of oncology. 2001, Vol 12, pp 63-68, issn 0923-7534, SUP1Conference Paper

Mitomycin C and Vinblastine in combination with Amifostine in metastatic breast : A cancer a feasibility study of the EORTC - Investigational Drug Branch for Breast Cancer (IDBBC)KUSENDA, Z; KERGER, J; AWADA, A et al.Supportive care in cancer. 1997, Vol 5, Num 5, pp 414-416, issn 0941-4355Article